Department of Interventional Neuroradiology, Erasme University Hospital, Brussels, Belgium.
Department of Radiology, Leuven University Hospital, Leuven, Belgium.
Neurosurgery. 2022 Dec 1;91(6):913-919. doi: 10.1227/neu.0000000000002129. Epub 2022 Oct 17.
The first-pass effect in endovascular thrombectomy (EVT) has been associated with better clinical outcomes and decreased stroke progression in large vessel occlusion but has not been evaluated in distal, medium vessel occlusions (DMVOs).
To assess the impact on clinical outcome and stroke progression of the modified first-pass effect (defined as a successful first-pass [modified Thrombolysis In Cerebral Infarction 2b/2c/3] revascularization) in patients who underwent EVT for a primary DMVOs.
We collected data from consecutive patients who underwent EVT for a primary DMVO at a single large academic center. We compared the rate of good clinical outcome (modified Rankin Scale of 0-2 at 3 months) and stroke progression between patients who demonstrated modified first-pass effect (mFPE) vs those who did not (no-mFPE).
Between January 2018 and January 2021, we included 60 patients who underwent EVT for an acute ischemic stroke with a primary DMVO. Overall, mFPE was achieved in 32% (19/60) of EVTs. The mFPE was associated with a higher rate of good clinical outcome compared with no-mFPE (89% vs 46%, odds ratio = 16.04 [2.23-115.39], P = .006 in multivariate analysis). Final stroke volume was less among mFPE patients (6.9 mL [4.7-13.6] vs 23 mL [14.6-47], P = .001) as was stroke progression (6.8 mL [4-12.1] vs 17.8 mL [8.1-34.9], P = .016). The mFPE was still associated with higher rates of good clinical outcome when compared with patients reaching an modified Thrombolysis In Cerebral Infarction score ≥2b in more than 1 pass (89% vs 53%; odds ratio = 7.37 [1.43-38.08], P = .017).
The mFPE may be associated with better clinical outcomes and lower stroke progression in DMVO.
血管内血栓切除术(EVT)中的首次通过效应与大血管闭塞中的更好的临床结果和减少卒中进展有关,但尚未在远端、中等血管闭塞(DMVO)中进行评估。
评估在接受 EVT 治疗原发性 DMVO 的患者中,改良的首次通过效应(定义为成功的首次通过[改良的脑梗死溶栓 2b/2c/3]再通)对临床结果和卒中进展的影响。
我们收集了在一家大型学术中心接受 EVT 治疗原发性 DMVO 的连续患者的数据。我们比较了显示改良首次通过效应(mFPE)与未显示改良首次通过效应(no-mFPE)的患者之间的良好临床结果(3 个月时改良 Rankin 量表为 0-2)和卒中进展的发生率。
在 2018 年 1 月至 2021 年 1 月期间,我们纳入了 60 例接受 EVT 治疗的急性缺血性卒中伴原发性 DMVO 患者。总体而言,32%(19/60)的 EVT 实现了 mFPE。与 no-mFPE 相比,mFPE 与更高的良好临床结果率相关(89% vs 46%,优势比=16.04[2.23-115.39],P=0.006 在多变量分析中)。mFPE 患者的最终卒中体积较小(6.9 mL[4.7-13.6] vs 23 mL[14.6-47],P=0.001),卒中进展也较少(6.8 mL[4-12.1] vs 17.8 mL[8.1-34.9],P=0.016)。与达到 1 次以上改良脑梗死溶栓评分≥2b 的患者相比,mFPE 仍与更高的良好临床结果率相关(89% vs 53%;优势比=7.37[1.43-38.08],P=0.017)。
mFPE 可能与 DMVO 中的更好的临床结果和更低的卒中进展相关。